Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use

International Journal of Antimicrobial Agents

Volumn 35, Issue 3, 2010, Pages 261-264

  Lee, Yuarn Jang ^a   Liu, Hsin Yi ^a   Lin, Yi Chun ^a   Sun, Kuo Lun ^a   Chun, Chi Li ^a   Hsueh, Po Ren ^b  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Ciprofloxacin; Fluoroquinolones; Levofloxacin; Pseudomonas aeruginosa; Resistance

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG USE; DRUG UTILIZATION; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TAIWAN;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; FLUOROQUINOLONES; HOSPITALS; HUMANS; OFLOXACIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TAIWAN;

EID: 73849125933     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.11.007     Document Type: Article

References (15)

1. Richards M.J., Edwards J.R., Culver D.H., and Gaynes R.P. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 27 (1999) 887-892
2. Hsueh P.R., Chen M.L., Sun C.C., Chen W.H., Pan H.J., Yang L.S., et al. Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999. Emerg Infect Dis 8 (2002) 63-68
3. Harris A.D., Smith D., Johnson J.A., Bradham D.D., and Roghmann M.C. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 34 (2002) 340-345
4. Micek S.T., Lloyd A.E., Ritchie D.J., Reichley R.M., Fraser V.J., and Kollef M.H. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 49 (2005) 1306-1311
5. Polk R.E., Johnson C.K., McClish D., Wenzel R.P., and Edmond M.B. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 39 (2004) 497-503
6. Mohr J.F., Jones A., Ostrosky-Zeichner L., Wanger A., and Tillotson G. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002. Int J Antimicrob Agents 24 (2004) 346-351
7. Van Eldere J. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J Antimicrob Chemother 51 (2003) 347-352
8. Kaye K.S., Kanafani Z.A., Dodds A.E., Engemann J.J., Weber S.G., and Carmeli Y. Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 50 (2006) 2192-2196
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Document M100-S19. Wayne, PA: CLSI; 2009.
10. Akasaka T., Tanaka M., Yamaguchi A., and Sato K. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother 45 (2001) 2263-2268
11. Livermore D.M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin Infect Dis 34 (2002) 634-640
12. Ohmagari N., Hanna H., Graviss L., Hackett B., Perego C., Gonzalez V., et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 104 (2005) 205-212
13. Hansen G.T., Zhao X., Drlica K., and Blondeau J.M. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicrob Agents 27 (2006) 120-124
14. Bhavnani S.M., Callen W.A., Forrest A., Gilliland K.K., Collins D.A., Paladino J.A., et al. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals. Am J Health Syst Pharm 60 (2003) 1962-1970
15. Richard P., Delangle M.H., Raffi F., Espaze E., and Richet H. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant Gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 32 (2001) 162-166